November 16, 2017 7:50 pm ET Egalet Announces Positive Top-Line Results from Phase 3 Safety Study Evaluating Safety of Egalet-002
In addition, a phase 3 trial evaluating the safety and efficacy of Egalet-002 in patients with moderate-to-severe chronic pain is expected to be completed by year end.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.